VIRALEZE Nasal Spray Approved in Malaysia
Released
Released
Announcement PDF
VIRALEZE™ Nasal Spray Approved in Malaysia
•
Starpharma has achieved regulatory approval for its antiviral nasal spray
product, VIRALEZE™, in Malaysia
•
Starpharma is progressing discussions with potential commercial partners in
Malaysia, with the view of distributing VIRALEZE™ through local retail outlets
including pharmacies
Melbourne, Australia; 5 June 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today
announces that it has achieved regulatory approval for its antiviral nasal spray product,
VIRALEZE™, in Malaysia. The registration will allow Starpharma and its commercial partners
to market and sell the product in Malaysia, a country with a population of over 33 million.
VIRALEZE™ has been well received in Asia to date, following successful launches of the
product locally in Vietnam, Hong Kong and Macau. Starpharma continues discussions with
potential commercial partners in Malaysia as well as other parts of Asia and countries across
the world.
VIRALEZE™ is a nasal spray that works by physically trapping and blocking cold/respiratory
viruses in the nasal cavity. Multiple nonclinical studies have shown that VIRALEZE™ traps
and blocks a broad spectrum of respiratory viruses, including human coronaviruses, influenza
viruses, rhinoviruses, and respiratory syncytial virus (RSV). Starpharma is also currently
conducting a post-market clinical study of VIRALEZE™ in people with COVID-19. The clinical
study, which will examine the antiviral activity and ability of VIRALEZE™ to reduce viral load
over a 7-day period, is underway in the United Kingdom and has recruited more than 80% of
the target number of participants to date.
Starpharma now has registrations for VIRALEZE™ nasal spray covering more than 35
countries, including Europe and the U.K., and has made the product available in pharmacies,
retail outlets and online in certain markets.
Dr Jackie Fairley, CEO of Starpharma, commented: “Starpharma is pleased to have added
another Asian market to the growing list of countries where VIRALEZE™ nasal spray is
registered, having now completed the approval process for VIRALEZE™ in Malaysia.
VIRALEZE™ will be available immediately to consumers in Malaysia through an online
webstore and Starpharma also plans to make the product available locally through retail
outlets, including pharmacies, as it is in Vietnam, Hong Kong, Macau, U.K., and Italy. We are
encouraged by the positive uptake of VIRALEZE™ in Asia and look forward to launching the
product in Malaysia as soon as practicable.”
VIRALEZE™ Nasal Spray
VIRALEZE™ is a nasal spray that physically traps and blocks cold/respiratory viruses in the nasal cavity. VIRALEZE™ is
applied in the nose where it forms a physical moisture barrier between viruses and the nasal mucous membrane that
traps and blocks virus.
Starpharma now has registrations for VIRALEZE™ nasal spray covering more than 35 countries, including Europe and
the U.K., and has made the product available in pharmacies, retail outlets and online in certain markets. Product claims
may differ by market. Starpharma markets VIRALEZE™ via commercial arrangements in countries in Europe, Asia, and
the Middle East. VIRALEZE™ is not approved for use or supply in Australia.
This announcement is intended for investors and market participants only. VIRALEZE™ is not approved for use or supply
in Australia.
About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a biopharmaceutical company, focussed on the
development of pharmaceutical and medical products for unmet patient needs, including in the areas of oncology and
infectious diseases.
Starpharma’s innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically
manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of
branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications.
Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing
pharmaceuticals. Starpharma’s portfolio includes multiple clinical stage oncology products, which utilise its Dendrimer
Enhanced Product (‘DEP®’) drug delivery technology; and marketed products, including VIRALEZE™ and VivaGel® BV,
which utilise SPL7013, a proprietary dendrimer with antimicrobial properties.
Starpharma’s DEP® drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and
to reduce drug-related toxicities through controlled and specified drug delivery.
In addition to Starpharma’s internal DEP® programs, Starpharma has multiple DEP® partnerships with international
biopharmaceutical companies including AstraZeneca (oncology); MSD (antibody drug conjugates); Chase Sun (antiinfectives); and other world leading pharmaceutical companies. Due to the broad applicability and optionality of
Starpharma’s DEP® platform, partnered DEP® programs have the potential to generate significant future milestones and
royalties.
Starpharma’s topical antiviral nasal spray, VIRALEZE™, is now registered in more than 30 countries*, including in Europe,
in the UK, and in Southeast Asia. Starpharma’s novel non-antibiotic vaginal gel, VivaGel® BV, for treatment of bacterial
vaginosis (BV) and prevention of recurrent BV, is registered in more than 45 countries, including in the UK, in Europe, in
Southeast Asia, South Africa, Australia and New Zealand.
* Note: VIRALEZE™ is not approved for use or supply in Australia.
Starpharma.com | Twitter | LinkedIn
Media: Sumit Media
Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au
Starpharma Holdings Limited
Dr Jackie Fairley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by the
Chairman, Mr Rob Thomas.
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of
forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”,
“targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or
similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of
product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding
any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for
sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval
and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain
or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public
pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial
results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is
providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other
clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance
and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing
contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty
or guarantee as to the past, present or the future performance of any Starpharma product.
2
Share your feedback
Discover